Arpa-H O1 sbir phase II - novel telehealth instruments for assessing pediatric well-being. Project title: digital assessment of children's conditions using artificial intelligence ("daccs AI")

Ended Definitive Contract Awarded Last action

Contract number
75N91023C00045
Awardee
Awarding agency
Obligated
$3,480,960

Award facts

Contract value 100% obligated
$3,480,960.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Cambridge, MA 02142, USA
Research
SBIR Program Phase II Action
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00005 -$20
Other Administrative Action P00004 · This no-cost unilateral administrative modification will be executed under far 43.103(B) unilateral is to: a. Transfer the contracting office from NIH NCI to… $0
Transfer Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $3,480,980

About this award

Belletorus Corporation, a small business based in Cambridge, MA, has been awarded a $3.48M Phase II Small Business Innovation Research (SBIR) contract by the Advanced Research Projects Agency for Health (ARPA-H) under the National Institutes of Health. The contract, with an ultimate completion date of September 17, 2025, supports development of "Digital Assessment of Children's Conditions Using Artificial Intelligence" (DACCS AI), a novel telehealth instrument designed to assess pediatric well-being. This award originated from ARPA-H's May 2023 pre-solicitation notice (75N91023R00041), which sought innovative research from small businesses to advance the agency's mission in areas including telehealth technologies and disruptive health solutions. The contract is set aside for total small businesses with no more than 500 employees.

The award has recently undergone a no-cost unilateral administrative modification under FAR 43.103(b) to transfer contracting oversight from the National Cancer Institute (NCI) to ARPA-H, including updates to the contracting officer and buyer information. This modification reflects organizational alignment within the federal contracting infrastructure while maintaining the original firm-fixed-price contract terms and project scope. The Phase II designation indicates the project has successfully completed proof-of-concept validation and is now advancing toward commercial viability and deployment of the pediatric assessment technology.

Quick answers

Who was awarded contract 75N91023C00045?

75N91023C00045 was awarded to Belletorus Corporation by National Institutes of Health (Department of Health and Human Services) on September 18, 2023.

How much is contract 75N91023C00045 worth?

The government has obligated $3,480,960 on 75N91023C00045.

Was contract 75N91023C00045 competed?

The extent of competition for 75N91023C00045 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award